ArticleACS biomaterials science & engineering2023
Polymer Lung Surfactants Attenuate Direct Lung Injury in Mice.
Article in ACS biomaterials science & engineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 12 citations in OpenAlex.
- Surfactant therapy for the treatment of acute respiratory distress syndrome: time to revisit?Journal of applied physiology (Bethesda, Md. : 1985) · 2026Review
- Advances in natural product-based nanoparticles for the treatment of acute lung injury.Materials today. Bio · 2025Review
- Elevated KLF2 and YKL-40 with reduced vitamin A as predictive biomarkers for severity and prognosis in neonatal respiratory distress syndrome.American journal of translational research · 2025Article
- Nanotherapy therapy for acute respiratory distress syndrome: a review.Frontiers in medicine · 2024Review
- Effect of temperature on the air-water surface mechanical behavior of water-spread block copolymer micelles.Soft matter · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
If not properly managed, acute lung injuries, either through direct or indirect causes, have the potential to present serious risk for many patients worldwide. One of the mechanisms for the transition from acute lung injury (ALI) to the more serious acute respiratory distress syndrome (ARDS) is the deactivation of the native lung surfactant by injury-induced infiltrates to the alveolar space. Currently, there are no surfactant replacement therapies that are used to treat ALI and subsequent ARDS. In this paper, we present an indepth efficacy study of using a novel polymer lung surfactant (PLS, composed of poly(styrene-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.